Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q15493

UPID:
RGN_HUMAN

ALTERNATIVE NAMES:
Gluconolactonase; Senescence marker protein 30

ALTERNATIVE UPACC:
Q15493; A4FTW1; A8K271; Q53FC9; Q5JRR5

BACKGROUND:
Regucalcin, identified by its alternative name Gluconolactonase, is crucial for calcium-binding and modulation of Ca(2+) signaling. This protein's enzymatic activity extends to the hydrolysis of various sugar lactones and synthetic compounds, underscoring its importance in metabolic processes and cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Regucalcin offers a promising avenue for drug discovery. Its central role in modulating calcium-dependent signaling and processes could be pivotal in developing novel therapeutic interventions for diseases linked to calcium dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.